Abstract | OBJECTIVE: To assess the long-term outcome of patients treated with serial intrafistular injections of autologous bone marrow-derived mesenchymal stem cells (MSCs) for refractory Crohn fistulas in terms of safety and efficacy. PATIENTS AND METHODS: Starting from January 10, 2007, through June 30, 2014, clinical evaluation, calculation of the Crohn disease activity index (CDAI), therapeutic management, and documentation of adverse events in 8 of the 10 patients (5 men; median age, 37 years) who had been injected locally with MSCs were prospectively recorded for 72 months. Cumulative probabilities of fistula recurrence and medical or surgical treatment were estimated using a Kaplan-Meier method, whereas differences among the pre- and post-MSC CDAI values were calculated with the Mann-Whitney U test. RESULTS: Following disease remission observed after 12 months from MSC treatment (P<.001), the mean CDAI score increased significantly during the subsequent 2 years (P=.007), and was then followed by a gradual decrease, with the patients achieving remission again (P=.02) at the end of the 5-year follow-up. The probability of fistula relapse-free survival was 88% at 1 year, 50% at 2 years, and 37% during the following 4 years, and the cumulative probabilities of surgery- and medical-free survival were 100% and 88% at 1 year, 75% and 25% at 2, 3, and 4 years, and 63% and 25% at 5 and 6 years, respectively. No adverse events were recorded. CONCLUSION: Locally injected MSCs constitute a safe therapy that rescues refractory patients and regains responsiveness to drugs previously proved ineffective.
|
Authors | Rachele Ciccocioppo, Alessandra Gallia, Adele Sgarella, Peter Kruzliak, Paolo G Gobbi, Gino Roberto Corazza |
Journal | Mayo Clinic proceedings
(Mayo Clin Proc)
Vol. 90
Issue 6
Pg. 747-55
(Jun 2015)
ISSN: 1942-5546 [Electronic] England |
PMID | 26046409
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved. |
Topics |
- Adult
- Aged
- Crohn Disease
(complications, therapy)
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Intestinal Fistula
(etiology, therapy)
- Male
- Mesenchymal Stem Cell Transplantation
(methods)
- Middle Aged
- Time Factors
- Treatment Outcome
- Young Adult
|